NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PharoahPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800–809.
BerlinerJLFayAM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns2007;16:241–260.
TrepanierAAhrensMMcKinnonW. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns2004;13:83–114.
EngC. PTEN hamartoma tumor syndrome (PTHS). In: PagonRAAdamMPArdingerHH eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed August 5 2014.
PilarskiRStephensJANossR. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet2011;48:505–512.
VargaEAPastoreMPriorT. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med2009;11:111–117.
LloydKM2ndDennisM. Cowden’s disease. A possible new symptom complex with multiple system involvement. Ann Intern Med1963;58:136–142.
NelenMRKremerHKoningsIB. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet1999;7:267–273.
PilarskiREngC. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet2004;41:323–326.
Riegert-JohnsonDLGleesonFCRobertsM. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract2010;8:6.
BubienVBonnetFBrousteV. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet2013;50:255–263.
SchafferJVKaminoHWitkiewiczA. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol2006;142:625–632.
JazaeriAALuKSchmandtR. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog2003;36:53–59.
HealdBMesterJRybickiL. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology2010;139:1927–1933.
Al-ThihliKPalmaLMarcusV. A case of Cowden’s syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol2009;6:184–189.
ZhouXPWaiteKAPilarskiR. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet2003;73:404–411.
AndresRHGuzmanRWeisJ. Lhermitte-Duclos disease with atypical vascularization—case report and review of the literature. Clin Neuropathol2009;28:83–90.
ButlerMGDasoukiMJZhouXP. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet2005;42:318–321.
HermanGEButterEEnrileB. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet A2007;143:589–593.
MarshDJCoulonVLunettaKL. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet1998;7:507–515.
TanMHMesterJPetersonC. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet2011;88:42–56.
PilarskiRBurtRKohlmanW. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst2013;105:1607–1616.
National Cancer Institute. Surveillance Epidemiology and End Results Program. SEER Stat Fact Sheets: Thyroid Cancer. Available at: http://seer.cancer.gov/statfacts/html/thyro.html. Accessed August 5 2014.